Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis

被引:26
作者
Lowes, Linda Pax [1 ]
Alfano, Lindsay [1 ]
Viollet, Laurence [1 ]
Rosales, Xiomara Quintero [1 ,2 ]
Sahenk, Zarife [1 ,2 ]
Kaspar, Brian K. [1 ,2 ]
Clark, K. Reed [1 ]
Flanigan, Kevin M. [1 ,2 ]
Mendell, Jerry R. [1 ,2 ]
McDermott, Michael P. [3 ]
机构
[1] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH 43205 USA
[2] Ohio State Univ, Coll Med, Dept Pediat & Neurol, Columbus, OH 43210 USA
[3] Univ Rochester, Sch Med & Dent, Rochester, NY USA
关键词
functional outcomes; maximum voluntary isometric contraction testing; sporadic inclusion-body myositis; strength; prognosis; surrogate measures; DUCHENNE MUSCULAR-DYSTROPHY; RANDOMIZED PILOT TRIAL; CORTICOSTEROID TREATMENT; NATURAL-HISTORY; DOUBLE-BLIND; INTRAVENOUS IMMUNOGLOBULIN; PREDNISONE; PLACEBO; DISEASE; PROGRESSION;
D O I
10.1002/mus.22321
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: In this study we address the challenging issue of potential use of muscle strength to predict function in clinical trials. This has immediate relevance to translational studies that attempt to improve quadriceps strength in sporadic inclusion-body myositis (sIBM). Methods: Maximum voluntary isometric contraction testing as a measure of muscle strength and a battery of functional outcomes were tested in 85 ambulatory subjects with sIBM. Results: Marked quadriceps weakness was noted in all patients. Strength was correlated with distance walked at 2 and 6 minutes. Additional correlations were found with time to get up from a chair, climb stairs, and step up on curbs. Conclusions: Quadriceps (knee extensor) strength correlated with performance in this large cohort of sIBM subjects, which demonstrated its potential to predict function in this disease. These data provide initial support for use of muscle strength as a surrogate for function, although validation in a clinical trial is required. Muscle Nerve, 2012
引用
收藏
页码:163 / 168
页数:6
相关论文
共 33 条
[1]   INCLUSION-BODY MYOSITIS - TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN [J].
AMATO, AA ;
BAROHN, RJ ;
JACKSON, CE ;
PAPPERT, EJ ;
SAHENK, Z ;
KISSEL, JT .
NEUROLOGY, 1994, 44 (08) :1516-1518
[2]   Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo [J].
Badrising, UA ;
Maat-Schieman, MLC ;
Ferrari, MD ;
Zwinderman, AH ;
Wessels, JAM ;
Breedveld, FC ;
van Doorn, PA ;
van Engelen, BGM ;
Hoogendijk, JE ;
Höweler, CJ ;
de Jager, AE ;
Jennekens, FGI ;
Koehler, PJ ;
de Visser, M ;
Viddeleer, A ;
Verschuuren, JJ ;
Wintzen, AR .
ANNALS OF NEUROLOGY, 2002, 51 (03) :369-372
[3]   Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy - Long-term effect [J].
Balaban, B ;
Matthews, DJ ;
Clayton, GH ;
Carry, T .
AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2005, 84 (11) :843-850
[4]   Pilot trial of etanercept in the treatment of inclusion-body myositis [J].
Barohn, RJ ;
Herbelin, L ;
Kissel, JT ;
King, W ;
McVey, AL ;
Saperstein, DS ;
Mendell, JR .
NEUROLOGY, 2006, 66 :S123-S124
[5]   Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade [J].
Biggar, WD ;
Harris, VA ;
Eliasoph, L ;
Alman, B .
NEUROMUSCULAR DISORDERS, 2006, 16 (04) :249-255
[6]  
Bohannon Richard W, 2006, J Geriatr Phys Ther, V29, P64
[7]   A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM [J].
Dalakas, MC ;
Koffman, B ;
Fujii, M ;
Spector, S ;
Sivakumar, K ;
Cupler, E .
NEUROLOGY, 2001, 56 (03) :323-327
[8]   Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study [J].
Dalakas, MC ;
Sonies, B ;
Dambrosia, J ;
Sekul, E ;
Cupler, E ;
Sivakumar, K .
NEUROLOGY, 1997, 48 (03) :712-716
[9]   Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications [J].
Greenberg, Steven A. .
NEUROLOGY, 2007, 69 (21) :2008-2019
[10]   The current status of treatment for inclusion-body myositis [J].
Griggs, RC .
NEUROLOGY, 2006, 66 :S30-S32